28.65
price up icon0.77%   0.22
after-market Dopo l'orario di chiusura: 28.65
loading
Precedente Chiudi:
$28.43
Aprire:
$29.23
Volume 24 ore:
160.31K
Relative Volume:
1.04
Capitalizzazione di mercato:
$787.78M
Reddito:
-
Utile/perdita netta:
$-69.47M
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
$-73.92M
1 W Prestazione:
+1.56%
1M Prestazione:
+11.13%
6M Prestazione:
+74.06%
1 anno Prestazione:
+0.00%
Intervallo 1D:
Value
$28.11
$29.50
Intervallo di 1 settimana:
Value
$26.12
$29.50
Portata 52W:
Value
$14.42
$31.00

Lenz Therapeutics Inc Stock (LENZ) Company Profile

Name
Nome
Lenz Therapeutics Inc
Name
Telefono
858-925-7000
Name
Indirizzo
445 MARINE VIEW AVE SUITE 320, DEL MAR
Name
Dipendente
0
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
LENZ's Discussions on Twitter

Lenz Therapeutics Inc Borsa (LENZ) Ultime notizie

pulisher
Oct 31, 2024

LENZ Therapeutics (LENZ) to Release Earnings on Wednesday - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Registration Open for CME/CE-Accredited Free Event Nov 7 - InvisionMag

Oct 31, 2024
pulisher
Oct 30, 2024

LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024 - The Manila Times

Oct 30, 2024
pulisher
Oct 30, 2024

LENZ Therapeutics Insider Buyers See Boost After Market Cap Rose US$97m - Simply Wall St

Oct 30, 2024
pulisher
Oct 29, 2024

Corxel and LENZ share positive results from Phase III China trial - The Pharma Letter

Oct 29, 2024
pulisher
Oct 28, 2024

LENZ reports positive Chinese study data for far-sightedness drug - MSN

Oct 28, 2024
pulisher
Oct 28, 2024

LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships - AOL

Oct 28, 2024
pulisher
Oct 28, 2024

Wescott Financial Advisory Group LLC Acquires 2,154 Shares of NVIDIA Co. (NASDAQ:NVDA) - Defense World

Oct 28, 2024
pulisher
Oct 28, 2024

Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews

Oct 28, 2024
pulisher
Oct 28, 2024

LENZ Therapeutics Shares Climb After Presbyopia Trial Hits Endpoints - MarketWatch

Oct 28, 2024
pulisher
Oct 27, 2024

CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100 - ForexTV.com

Oct 27, 2024
pulisher
Oct 27, 2024

CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial - The Bakersfield Californian

Oct 27, 2024
pulisher
Oct 27, 2024

VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV - ForexTV.com

Oct 27, 2024
pulisher
Oct 26, 2024

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives $35.40 Average Price Target from Analysts - MarketBeat

Oct 26, 2024
pulisher
Oct 22, 2024

Lenz Therapeutics announces FDA acceptance of NDA for LNZ100 - Yahoo Finance

Oct 22, 2024
pulisher
Oct 22, 2024

Mcf Energy Ltd (MCF-X) QuotePress Release - The Globe and Mail

Oct 22, 2024
pulisher
Oct 21, 2024

LENZ Therapeutics Shares Rise After FDA Accepts Application for Potential Eye Condition Treatment - Marketscreener.com

Oct 21, 2024
pulisher
Oct 21, 2024

Why LENZ Therapeutics Stock Hit A New 52-Week High Today - Benzinga

Oct 21, 2024
pulisher
Oct 21, 2024

One new option listing and ten option delistings on October 21st - TipRanks

Oct 21, 2024
pulisher
Oct 21, 2024

LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia - The Manila Times

Oct 21, 2024
pulisher
Oct 21, 2024

LENZ Therapeutics, Inc. Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia - Marketscreener.com

Oct 21, 2024
pulisher
Oct 18, 2024

Behind the Bell: LENZ Therapeutics - Nasdaq

Oct 18, 2024
pulisher
Oct 18, 2024

FY2028 Earnings Estimate for LENZ Issued By Leerink Partnrs - MarketBeat

Oct 18, 2024
pulisher
Oct 16, 2024

Presbyopia Market on Track for Major Expansion by 2034, - openPR

Oct 16, 2024
pulisher
Oct 16, 2024

Presbyopia Market on Track for Major Expansion by 2034, According to DelveInsight | Eyenovia, Orasis Pharma, Ocuphire Pharma, Novartis, Visus Therapeutics - The Globe and Mail

Oct 16, 2024
pulisher
Oct 16, 2024

Preterm Birth and PROM Testing Market Expected to Grow at 8.6% CAGR, projected to Reach USD 562.1 million by 2034 | States Transparency Market Research, Inc. - Yahoo Finance

Oct 16, 2024
pulisher
Oct 16, 2024

Lenz Co. stock soars to 52-week high, hits $26.18 By Investing.com - Investing.com Canada

Oct 16, 2024
pulisher
Oct 15, 2024

Lucy Therapeutics Appoints Kim Drapkin as Board Chair - BioSpace

Oct 15, 2024
pulisher
Oct 15, 2024

Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences - Yahoo Finance

Oct 15, 2024
pulisher
Oct 15, 2024

TJX Companies (TJX-N) QuotePress Release - The Globe and Mail

Oct 15, 2024
pulisher
Oct 14, 2024

Dimensional Fund Advisors LP Increases Holdings in Koss Co. (NASDAQ:KOSS) - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

Creative Planning Buys 296 Shares of PVH Corp. (NYSE:PVH) - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

ABVC BioPharma, Inc. (NASDAQ:ABVC) Sees Large Increase in Short Interest - Defense World

Oct 14, 2024
pulisher
Oct 13, 2024

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired by The Manufacturers Life Insurance Company - MarketBeat

Oct 13, 2024
pulisher
Oct 11, 2024

Neumora Therapeutics executive sells over $200k in company stock By Investing.com - Investing.com Australia

Oct 11, 2024
pulisher
Oct 11, 2024

Neumora Therapeutics executive sells over $200k in company stock - Investing.com India

Oct 11, 2024
pulisher
Oct 11, 2024

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Insider Robert A. Lenz Sells 5,563 Shares - MarketBeat

Oct 11, 2024
pulisher
Oct 11, 2024

Neumora Therapeutics Inc. [NMRA] Records 50-Day SMA of $12.22 - Knox Daily

Oct 11, 2024
pulisher
Oct 11, 2024

Marshall Wace LLP Invests $390,000 in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat

Oct 11, 2024
pulisher
Oct 09, 2024

Market Momentum Report: Neumora Therapeutics Inc. (NMRA)’s Positive Close at 14.74 - The Dwinnex

Oct 09, 2024
pulisher
Oct 08, 2024

LENZEyeing A Slice Of The Presbyopia Pie - RTTNews

Oct 08, 2024
pulisher
Oct 04, 2024

LENZ stock touches 52-week high at $25.85 amid market optimism - Investing.com Canada

Oct 04, 2024
pulisher
Oct 03, 2024

Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases - ForexTV.com

Oct 03, 2024
pulisher
Oct 02, 2024

Potential Price Increase for Neumora Therapeutics Inc. (NMRA) After Recent Insider Activity - Knox Daily

Oct 02, 2024
pulisher
Oct 01, 2024

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Oct 01, 2024
pulisher
Oct 01, 2024

Canada Pension Plan Investment Board Makes New $26,000 Investment in Mesa Laboratories, Inc. (NASDAQ:MLAB) - Defense World

Oct 01, 2024
pulisher
Oct 01, 2024

Xponance Inc. Cuts Position in Darling Ingredients Inc. (NYSE:DAR) - Defense World

Oct 01, 2024
pulisher
Oct 01, 2024

EURETINA 2024: CRISPR-Cas mediated base editing approaches for CRB1 related retinal dystrophy - Modern Retina

Oct 01, 2024
pulisher
Sep 30, 2024

LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences - The Manila Times

Sep 30, 2024
pulisher
Sep 30, 2024

Metavesco Acquires Assets From Epic Labor - The Manila Times

Sep 30, 2024
pulisher
Sep 28, 2024

Achieve, INmune, Lenz gain on bullish initiations from Raymond James - MSN

Sep 28, 2024

Lenz Therapeutics Inc Azioni (LENZ) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Lenz Therapeutics Inc Azioni (LENZ) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Chevallard Daniel R.
Chief Financial Officer
May 14 '24
Buy
15.68
3,188
49,988
3,188
MCCOLLUM JAMES W
Director
May 13 '24
Buy
15.99
31,332
501,093
525,565
RA CAPITAL MANAGEMENT, L.P.
Director
Mar 21 '24
Buy
15.03
998,009
15,000,075
3,319,339
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Capitalizzazione:     |  Volume (24 ore):